Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

References

• FornerAReigMBruixJHepatocellular carcinomaLancet2018391101271301131429307467
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• JohnsonPJQinSParkJWBrivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL studyJ Clin Oncol201331283517352423980084
   PubMed Web of Science ®Google Scholar
• ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trialJ Clin Oncol201331324067407524081937
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTLinifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized Phase III trialJ Clin Oncol201533217217925488963
   PubMed Web of Science ®Google Scholar
• ZhuAXRosmorducOEvansTRSearch: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinomaJ Clin Oncol201533655956625547503
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKNiedzwieskiDKnoxJJPhase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)J Clin Oncol2016344_Suppl192192
   Web of Science ®Google Scholar
• VilgrainVPereiraHAssenatEEfficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trialLancet Oncol201718121624163629107679
   PubMed Web of Science ®Google Scholar
• ChowPKHGandhiMTanSBSIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinomaJ Clin Oncol201836191913192129498924
   PubMed Web of Science ®Google Scholar
• KudoMFinnRSQinSLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trialLancet2018391101261163117329433850
   PubMed Web of Science ®Google Scholar
• LlovetJMDecaensTRaoulJLBrivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized Phase III BRISK-PS studyJ Clin Oncol201331283509351623980090
   PubMed Web of Science ®Google Scholar
• ZhuAXKudoMAssenatEEffect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialJAMA20143121576725058218
   PubMed Web of Science ®Google Scholar
• ZhuAXParkJORyooBYRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (reach): a randomised, double-blind, multicentre, Phase 3 trialLancet Oncol201516785987026095784
   PubMed Web of Science ®Google Scholar
• RimassaLAssenatEPeck-RadosavljevicMTivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a Phase 3, randomised, placebo-controlled studyLancet Oncol201819568269329625879
   PubMed Web of Science ®Google Scholar
• KobayashiSUeshimaKMoriguchiM619OJET-HCC: a Phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinomaAnn Oncol201728suppl_5v209v268
   Google Scholar
• Abou-AlfaGKQinSRyooBYPhase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinomaAnn Oncol20182961402140829659672
   PubMed Web of Science ®Google Scholar
• BruixJQinSMerlePRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trialLancet201738910064566627932229
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKMeyerTChengALCabozantinib in patients with advanced and progressing hepatocellular carcinomaN Engl J Med20183791546329972759
   PubMed Web of Science ®Google Scholar
• ZhuAXKangYKYenCJRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol2019118 [Epub ahead of print]
   Web of Science ®Google Scholar
• El-KhoueiryABSangroBYauTNivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trialLancet2017389100882492250228434648
   PubMed Web of Science ®Google Scholar
• CrocenziTSEl-KhoueiryABYauTCNivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepato-cellular carcinoma (HCC): CheckMate 040 studyJ Clin Oncol20173515_suppl4013
   Web of Science ®Google Scholar
• ZhuAXFinnRSEdelineJPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trialLancet Oncol201819794095229875066
   PubMed Web of Science ®Google Scholar
• KudoMLenvatinib may drastically change the treatment landscape of hepatocellular carcinomaLiver Cancer20187111929662829
   PubMed Web of Science ®Google Scholar
• IkedaMOkusakaTMitsunagaSSafety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinomaClin Cancer Res20162261385139426500236
   PubMed Web of Science ®Google Scholar
• IkedaKKudoMKawazoeSPhase 2 study of lenvatinib in patients with advanced hepatocellular carcinomaJ Gastroenterol201752451251927704266
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJModified RECIST (mRECIST) assessment for hepatocellular carcinomaSemin Liver Dis2010301526020175033
   PubMed Web of Science ®Google Scholar
• TamaiTHayatoSHojoSDose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure–response analysesJ Clin Pharmacol20175791138114728561918
   PubMed Web of Science ®Google Scholar
• KudoMFinnRSQinSLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trialLancet2018391101261163117329433850
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• FinnRSKudoMChengA-LLBA30Analysis of serum biomarkers (BM) in patients (PTS) from a Phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)Ann Oncol201728suppl_5
   Google Scholar
• FinnRSKudoMChengA-LFinal analysis of serum biomarkers in patients from the Phase 3 study of lenvatinib in unresectable hepatocellular carcinoma (REFLECT)Ann Oncol201829Suppl abstr: 59PD
   Google Scholar
• KudoMIzumiNKanekoSA cost-effectiveness analysis of lenvatinib compared with sorafenib in unresectable hepatocellular carcinoma allowing for AFP adjustment in overall survival in Japan from the REFLECT Phase 3 clinical trial12th ILCA annual conferenceLondonSeptember 14–16, 2018 abstr: O-021
   Google Scholar
• NomanMZDesantisGJanjiBPD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationJ Exp Med2014211578179024778419
   PubMed Web of Science ®Google Scholar
• ChenYRamjiawanRRReibergerTCXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceHepatology20156151591160225529917
   PubMed Web of Science ®Google Scholar
• TermeMColussiOMarcheteauETanchotCTartourETaiebJModulation of immunity by antiangiogenic molecules in cancerClin Dev Immunol2012201249292023320019
   PubMedGoogle Scholar
• RiveraLBMeyronetDHervieuVFrederickMJBergslandEBergersGIntratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapyCell Rep201511457759125892230
   PubMed Web of Science ®Google Scholar
• ManningEAUllmanJGLeathermanJMA vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismClin Cancer Res200713133951395917606729
   PubMed Web of Science ®Google Scholar
• TermeMPernotSMarcheteauEVEGFA–VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancerCancer Res201373253954923108136
   PubMed Web of Science ®Google Scholar
• YasudaSShoMYamatoISimultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivoClin Exp Immunol2013172350050623600839
   PubMed Web of Science ®Google Scholar
• PishvaianMJLeeMSRyooB-YLBA26Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)Ann Oncol201829suppl_8ix46ix66
   Google Scholar
• SteinSPishvaianMJLeeMSSafety and clinical activity of 1L atezolizumab + bevacizumab in a Phase Ib study in hepatocellular carcinoma (HCC)J Clin Oncol20183615_suppl4074
   Web of Science ®Google Scholar
• RocheFDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) [media release]Roche Group Media Relations2018 [July18]. Available from: https://www.roche.com/media/releases/med-cor-2018-07-18.htm
   Google Scholar
• IkedaMSungMWKudoMA Phase 1B trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (PTS) with unresectable hepatocellular carcinoma (uHCC)J Clin Oncol20183615_suppl40764076
   Web of Science ®Google Scholar
• MerckEisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell CarcinomaEisai Public Relations Department2018 [January 09]. Available from: https://investors.merck.com/news/press-release-details/2018/Eisai-and-Merck-Receive-Breakthrough-Therapy-Designation-from-FDA-for-LENVIMA-lenvatinib-mesylate-and-KEYTRUDA-pembrolizumab-as-Combination-Therapy-for-Advanced-and-or-Metastatic-Renal-Cell-Carcinoma-/default.aspx
   Google Scholar
• GallePRFornerALlovetJMMazzaferroVPiscagliaFRaoulJLSchirmacherPVilgrainVEASL clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol201869118223629628281
   PubMed Web of Science ®Google Scholar
• YamamotoYMatsuiJMatsushimaTLenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageVasc Cell2014611825197551
   PubMedGoogle Scholar
• FinnRSMerlePGranitoAOutcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the Phase III RESORCE trialJ Hepatol201869235335829704513
   PubMed Web of Science ®Google Scholar
• LamarcaAMendiolaMBarriusoJHepatocellular carcinoma: exploring the impact of ethnicity on molecular biologyCrit Rev Oncol Hematol2016105657227372199
   PubMed Web of Science ®Google Scholar
• PersoneniNRimassaLHepatocellular carcinoma: a global disease in need of individualized treatment strategiesJ Oncol Pract201713636836928605613
   PubMed Web of Science ®Google Scholar